1. Home
  2. Consortium


CIRMMP (Consorzio Interuniversitario Risonanze Magnetiche di Metalloproteine Paramagnetiche) was founded in 1994 among the universities of Florence, Siena and Bologna to develop and coordinate resources in a scientific field of growing interest, the study of metalloproteins and metalloenzymes.

CIRMMP manages and partially owns one of the most well-equipped NMR laboratories in the world: CERM (Centro di Risonanze Magnetiche). The center is equipped with a 900 MHz, 800 MHz, 700 MHz WB, 2 x 700 MHz, 2 x 600 MHz, a 500 MHz and a 400 MHz magnet, besides other routine instruments, as well as three relaxometers unique in the world.  The 500, 700, 800 and 900 MHz magnets are equipped with cryoprobes. Biophysical instrumentation such as absorbtion and CD spectroscopy fluorescence, microcalorimetry, and stopped flow tools are operative at CERM, whereas EPR mass spectroscopy and X-ray facilities are also available in flanking laboratories.CIRMMP supports protein production with a well-equipped and robotized molecular biology laboratory for high throughput production. CIRMMP has provided a service for magnetic resonance at the European level since 1994, and also supports a national service for private and public research institutions through a national scientific committee.

The research activity at CIRMMP encompasses bioinformatics, structural genomics and structural biology, pharmaceutical development, metabolomics, advancements in NMR methodologies, and relaxometry. CIRMMP has a long tradition of excellence and uniqueness in the field of metalloproteins and in particular on paramagnetic targets.The CIRMMP research team has also developed standardised protocols for handling biological fluids and for tissue and cell extraction in metabolomics research in collaboration with Bruker BioSpin. They have developed proprietary and absolutely innovative software for data handling and multivariate statistical analysis. The investigation of the metabolomic “fingerprint” is a powerful mean to study the correlation between various pathologies and the metabolites and their relative variations. Being the discrimination between “normal” and “non normal” subjects, that is finding differences between healthy and ill or potentially at risk subjects, one of the ultimate aims of metabolomic studies CIRMMP research team are studying the fingerprint of plasma/serum, urine, saliva and tissues samples from various areas of interest in the biomedical field. The primary current metabolomic projects are:

• Identification of different metabolic phenotypes in humans
• Celiac disease and potential celiac disease
• Broncho-pulmonary obstructive diseases
• Study on metabolic fingerprint of cardiovascular risk
• New statistical methods for data analysis and clustering
• Prognostic studies on patients with metastatic colorectal cancer
• Analysis of saliva samples for periodontal diseases fingerprinting
• Studies on inflammatory bowel diseases
• The use of metabolomics for samples quality assessment
• Evaluation of the ischemia effect on tissue metabolome
• Studies on oncology urological diseases
• Discovery of new biomarker for diagnosis and prognosis of melanoma